Dopamine Antagonists
Research News and Information

Saturday, November 21, 2009

Ex vivo [11C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro.

30 Oct 2009 Dopamine (DA) D2 receptor supersensitivity has been linked to an increase in the density of the D2 high-affinity state as measured in vitro. The two- affinity-state model of the D2 receptor predicts that the ex vivo specific binding of ... Read more...

Naloxone, but not flupenthixol, disrupts the development of conditioned ejaculatory preference in the male rat.

29 Sep 2009 Male rats display a conditioned preference to ejaculate with a female bearing an odor paired previously with copulation to ejaculation. The present study examined the role of endogenous opioid and dopamine systems in this preference. Male rats ... Read more...

Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2(High) receptor.

29 Sep 2009 The glutamate agonist LY404,039 has been used to treat schizophrenia. Because all currently used antipsychotics act on dopamine receptors, it was decided to examine whether this glutamate agonist also had an affinity for dopamine D2 receptors in ... Read more...

Latest indexed articles for 'Dopamine Antagonists'

These are the very latest articles for this heading:

• Ex vivo [11C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro. 30 Oct 2009
• Naloxone, but not flupenthixol, disrupts the development of conditioned ejaculatory preference in the male rat. 29 Sep 2009
• Glutamate agonist LY404,039 for treating schizophrenia has affinity for the dopamine D2(High) receptor. 29 Sep 2009
• Differential effects of topiramate on prefrontal glutamatergic transmission when combined with raclopride or clozapine. 29 Sep 2009
• Regulation of dynamin 2 and G protein-coupled receptor kinase 2 in rat nucleus accumbens during acute and repeated cocaine administration. 29 Sep 2009
• Patience is a virtue in the management of gastroesophageal reflux. 29 Sep 2009
• Acute neurobehavioral effects of toluene: involvement of dopamine and NMDA receptors. 14 Sep 2009
• A novel model and experimental analysis of hydrophilic and hydrophobic agent release from biodegradable polymers. 13 Sep 2009
• NCS-1 in the dentate gyrus promotes exploration, synaptic plasticity, and rapid acquisition of spatial memory. 8 Sep 2009
• In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. 30 Aug 2009
• Seizures associated with levofloxacin: case presentation and literature review. 24 Aug 2009
• Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism. 20 Aug 2009
• In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist. 20 Aug 2009
• Dopamine controls persistence of long-term memory storage. 19 Aug 2009
• Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [(123)I]IBZM SPECT. 13 Aug 2009
• Presynaptic action of neurotensin on dopamine release through inhibition of D(2) receptor function. 12 Aug 2009
• Roles of octopaminergic and dopaminergic neurons in appetitive and aversive memory recall in an insect. 2 Aug 2009
• Dopaminergic modulation of olfactory bulb processing affects odor discrimination learning in rats. 30 Jul 2009
• Tourette syndrome. 30 Jul 2009
• Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil. 30 Jul 2009

See a longer list of these articles.

Technical information about 'Dopamine Antagonists'

Definition: Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.

Registry Number: 0

Descriptor UI: D018492

Alternative terms: Dopamine Antagonists; Antagonists, Dopamine Receptor; Receptor Antagonists, Dopamine; Dopaminergic Antagonists; Dopamine Blockers; Blockers, Dopamine; Dopamine Receptor Antagonists; Antagonists, Dopamine; Antagonists, Dopaminergic;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications;

Tree Number: D27.505.519.625.150.175; D27.505.696.577.150.175;

History Note: 95

Technical Notes: DF: DOPAMINE ANTAG